“There is ample liquidity globally and as funds, especially the long only ones who were sitting on record levels of cash and had mostly stayed out of the rally, are now chasing performance through equity deals,” Sunil Khaitan, India head, Global Capital Markets at Bank of America, said in an email.
The IPO pipeline includes a spinoff of Gland Pharma Ltd. by Shanghai Fosun Pharmaceutical (Group) Co. that could raise as much as $800 million, according to people familiar with the matter. Kalyan Jewellers India Ltd., Computer Age Management Services, UTI Asset Management Co., Angel Broking Ltd. and the National Commodity and Derivatives Exchange Ltd. are also looking to list, according to PRIME Database.